• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Analyst Comment

Nightingale expands its strategic partnership with Terveystalo

By Antti LuiroHead of Nordic ER Development, Analyst
Nightingale Health

Translation: Original published in Finnish on 11/26/2025 at 7:15 pm EET.

Nightingale Health and Terveystalo announced a new strategic agreement on Tuesday, which continues and expands the companies' cooperation that began in 2021. With the new agreement, Nightingale's blood analysis technology will be made available to all Terveystalo customer groups, whereas previously it has mainly been used in health check-ups for occupational health customers. The agreement strengthens our view of the commercial value of the company's technology, but does not cause immediate pressure for changes in our forecasts.

The well-functioning partnership was expected to continue

Terveystalo has been Nightingale's most important commercial partner in the early stages and a key reference that its technology can be utilized in routine healthcare on a large scale. The companies' initial collaboration in building a consumer service was not successful, but the high-volume collaboration started at the beginning of 2024 in Terveystalo's routine occupational health check-ups has been very successful. According to the release, over 200,000 Finns have already received Nightingale's test results as part of Terveystalo's occupational health examinations. In light of the success of the occupational health cooperation, we expected the companies' partnership to at least continue, but the expansion of the partnership was a naturally positive addition to this.

The new expanded agreement improves the accessibility of Nightingale's service within Terveystalo's customer base and opens up new potential for commercial growth of the cooperation. However, the financial impact of the expansion depends on how widely Terveystalo's other customer groups adopt the service. If the service can be packaged as part of some of Terveystalo's existing high-volume services, we believe growth could also be very rapid. However, we are still awaiting further information on the new areas of use for the service and evidence of demand development in the new segments. The release supports our current growth forecasts, but does not create an immediate need for forecast changes.

Login required

This content is only available for logged in users

Create account

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures19.09.2025

202526e27e
Revenue4.77.98.8
growth-%7.7 %67.2 %12.1 %
EBIT (adj.)-19.4-17.3-15.2
EBIT-% (adj.)-413.7 %-220.4 %-172.8 %
EPS (adj.)-0.30-0.27-0.24
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Here are Antti’s comments on Nightingale’s profit warning. Inderes – 9 Jun 26 Nightingalen tulosvaroitus: Projektiviivästys siirtää liikevaihtoa...
6/9/2026, 5:19 AM
by Sijoittaja-alokas
12
Profit warning. The project is delayed but will be completed, says Suna. Inderes Sisäpiiritieto, tulosvaroitus: Nightingale Health jatkaa kasvuaan...
6/8/2026, 5:19 PM
by TZ
9
Antti and Miksu discussed how things are going with Nightingale Topics: (00:00) Introduction (00:13) Share price has tanked (02:14) Development...
6/4/2026, 1:22 PM
by Sijoittaja-alokas
5
In addition to that target price of €1.4, Antti’s analysis mentioned a wider range of €0.5–€5; in that sense, the difficulty of determining ...
6/4/2026, 7:04 AM
by J
6
I’ll argue against that a bit: an analyst must assume these deals and the progress of projects behind their forecasts if they expect revenue...
6/4/2026, 6:54 AM
by Antti Luiro
10
An interesting justification for the target price, considering that when deals are announced, they are announced, and they cannot be predicted...
6/4/2026, 6:04 AM
by Puutaheinää
4
Here is a new company report on Nightingale from Antti & Antti at Inderes following the latest news During the beginning of the year, Nightingale...
6/4/2026, 5:12 AM
by Sijoittaja-alokas
9